$3.5M grant to help Inovio further develop mass vaccine device

04/11/2013 | Genetic Engineering & Biotechnology News

The National Institute of Allergy and Infectious Diseases awarded Inovio Pharmaceuticals a $3.5 million grant to further develop a next-generation DNA vaccine delivery device that can simultaneously administer multiple synthetic vaccines through skin surface electroporation. The device is being co-developed with Chief Scientist Connie Schmaljohn of the Army Medical Research Institute of Infectious Diseases. The goal is to create a device that will allow fast vaccination of U.S. troops and protect the public from pandemic threats.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC